SOMERVILLE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known...

Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by...

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer...

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet...

Amgen wants its future drugs to be multispecific, and so the biopharmaceutical company selected Generate Biomedicines for a $1.9 billion...

Landus farmers will gain access to new carbon revenue stream and digital grain marketing tools AMES, Iowa (December 2, 2021) – Landus,...

Cambridge, Mass, November 18, 2021 – Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent...

Tessera’s Gene WritingTM Technology is Designed to Simultaneously Correct Multiple Genetic Mutations as well as to Write Genes in Their...

Laronde launched out of Flagship Labs this year with a lofty vision: to deliver as many as 100 new RNA medicines over the next 10 years....